Core Points - The company, Hainan Puli Pharmaceutical Co., Ltd., has had its stock and convertible bonds terminated from listing by the Shenzhen Stock Exchange due to false disclosures in its annual reports for 2021 and 2022, which amounted to a total of 669 million yuan, representing 73.83% of the total profits disclosed for those years [2][3] Group 1: Termination of Listing - The securities affected include common stock (stock code: 300630) and convertible bonds (bond code: 123099), with the termination decision effective from April 28, 2025 [2][3] - The company is required to ensure that its stock and convertible bonds can enter the delisting board for trading within 45 trading days after the termination [2] Group 2: Post-Termination Procedures - After the termination, the company has appointed Guotai Junan Securities Co., Ltd. as the lead broker for the trading of its stock and convertible bonds on the delisting board [4] - The company must handle the confirmation, registration, and custody of its securities in accordance with the regulations during the delisting process [4][5] Group 3: Investor Actions - Investors who submitted applications for conversion, redemption, or repurchase before the termination must resubmit their requests after the bonds are listed on the delisting board [1][5] - The company advises investors to complete the necessary procedures for the confirmation and registration of their securities to avoid delays in trading on the delisting board [5]

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. has received a notice regarding the termination of its stock and convertible bonds listing by the Shenzhen Stock Exchange, with trading entering a delisting arrangement starting April 28, 2025, and the last trading day set for May 21, 2025 [1][3]. Group 1: Termination of Listing - The Shenzhen Stock Exchange has decided to terminate the listing of the company's stock and convertible bonds, effective April 28, 2025, with a delisting trading period of fifteen trading days [1][3]. - The company submitted a review application for the termination decision on May 12, 2025, and received a notice of acceptance for the review application on May 21, 2025, with a review meeting scheduled for May 29, 2025 [3]. Group 2: Investor Guidance - Investors are advised that operations such as conversion, redemption, and repurchase cannot be executed during the delisting period and must be resubmitted after the bonds are listed on the delisting board [1][2]. - The company emphasizes that all relevant information should be verified through official announcements on designated information disclosure platforms [4].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：123099 | 普转退 债券简称：Z | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券终止上市暨摘牌的公告 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"）已被深圳证券交易所（以下简称"深交所"）决定 终止上市，并于 2025 年 4 月 28 日进入退市整理期交易，在退市整理期交易十 五个交易日，最后交易日为 2025 年 5 月 21 日。 2. 公司股票及可转债已被深交所决定终止上市，将在 2025 年 5 月 22 日被 摘牌。 3. 根据《退市公司可转换公司债券管理规定》第三十条，退市可转债自交 易所摘牌后至全国股转公司代为管理的退市板块（以下简称"退市板块"）挂 牌期间不得实施转股、赎回、回售等操作，在退市板块挂牌后需重新提交转股、 赎回、回售等相关信息。 投资者已提交转股、赎回、回售等操作 ...

| 证券代码：300630 | 证券简称：普利退 | 公告编号： | 2025-063 | | --- | --- | --- | --- | | 债券代码：123099 | 债券简称：Z 普转退 | | | 海南普利制药股份有限公司 关于公司收到《复核受理通知书》暨股票及可转换公司债券 摘牌的相关风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"）已被深圳证券交易所（以下简称"深交所"）决定终 止上市，并于 2025 年 4 月 28 日进入退市整理期交易，在退市整理期交易十五 个交易日，最后交易日为 2025 年 5 月 21 日。 2. 公司股票及可转债已被深交所决定终止上市，将在 2025 年 5 月 22 日被 摘牌。 3. 根据《深圳证券交易所理事会上诉复核委员会工作细则（2024 年修订）》 的相关规定，复核期间，深圳证券交易所作出的公司股票及可转债终止上市决 定不停止执行。 4. 根据《退市公司可转换公司债券管理规定》第三十条，退 ...

New Stock Offerings - ST New潮 (600777) is in the offer period from April 23, 2025, to May 22, 2025[1] - 普利退 (300630) has its last trading day on May 21, 2025, during the delisting arrangement period[1] - 成飞集成 (002190) reported severe abnormal fluctuations[1] Trading Alerts - 12 stocks are flagged for abnormal trading activities, including ST立方 (300344) and 利君股份 (002651)[1] - 3 stocks, including *ST凌云B (900957), are under special treatment due to financial issues[1] - 5 stocks, such as 湖南天雁 (600698) and 曼卡龙 (300945), are highlighted for trading alerts on May 21, 2025[1] Market Trends - The report indicates a significant number of stocks experiencing abnormal volatility, suggesting potential market instability[2] - The ongoing delisting process for certain stocks may impact investor sentiment and market liquidity[1]

Group 1 - The company, Hainan Puli Pharmaceutical Co., Ltd., received a decision from the Shenzhen Stock Exchange to terminate the listing of its stock and convertible bonds, effective from April 28, 2025, with the last trading day expected to be May 21, 2025 [1][2] - The convertible bonds will change their trading name to "Z Puli Convertible Bonds" on the last trading day, while the bond code "123099" will remain unchanged [2] Group 2 - The company emphasizes that all relevant information should be verified through official announcements on the Giant Tide Information Network and the official website of the share transfer system [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关于变更可转债证券简称的说明 | 证券代码：300630 | 证券简称：普利退 公告编号：2025-062 | | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | 海南普利制药股份有限公司 关于变更公司可转债证券简称的公告 公 司 郑 重 提 醒 广 大 投 资 者 ， 有 关 公 司 信 息 均 以 在 巨 潮 资 讯 网 （www.cninfo.com.cn）或股份转让系统官方网站（www.neeq.com.cn）刊登的相 关公告为准，敬请广大投资者理性投资，注意投资风险。 特此公告。 海南普利制药股份有限公司董事会 二〇二五年五月二十日 海南普利制药股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日收到 深圳证券交易所（以下简称"深交所"）《关于海南普利制药股份有限公司股票及 可转换公司债券终止上市的决定》（深证上〔2025〕357 号）。深圳证券交易所决 定终止公司股票及可转换公司债券（以下简称"可转债"）上市。公司股票及可 转债进入退市整理期的起始日为 ...

| 证券代码：300630 | 证券简称：普利退 | 公告编号： | 2025-061 | | --- | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第八次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，预计 最后交易日期为 2025 年 5 月 21 日。 3. 公司股票及可转债将在退市整理期交易十五个交易日，截至 2025 年 5 月 20 日公司股票及可转债已交易 14 个交易日，剩余 1 个交易日，交易期满将 被终止上市，敬请投资者审慎投资、注意风险。 4. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规 ...

New Stock Offerings - ST新潮 (600777) is undergoing a tender offer period from April 23, 2025, to May 22, 2025[1] - 普利退 (300630) and 普利转退 (123099) have 1 trading day remaining until the last trading day[1] - ST立方 (300344) and 利君股份 (002651) have recent announcements but no specific actions noted[1] Market Alerts - 成飞集成 (002190) reported severe abnormal fluctuations[1] - *ST凌云B (900957) and 恒而达 (300946) have recent announcements with no specific actions noted[1] - 华阳新材 (600281) and 江天化学 (300927) have recent announcements with no specific actions noted[1] Other Notable Stocks - *ST恒久 (002808) and 豪恩汽电 (301488) have recent announcements with no specific actions noted[1] - 安纳达 (002136) and 吉华集团 (603980) have recent announcements with no specific actions noted[1] - *ST双成 (002693) and 天汽模 (002510) have recent announcements with no specific actions noted[1]

板块涨幅居前的十大牛股分别是：阳光诺和（5.1%）、毕得医药（1.52%）、昭衍新药（0.88%）、药 康生物（0.85%）、诺泰生物（0.79%）、泓博医药（0.77%）、百诚医药（0.61%）、联化科技 （0.47%）、昊帆生物（0.45%）、泰格医药（0.4%）、美迪西（0.3%）、金凯生科（0.06%）、皓元医 药（0.05%）、迦南科技（0.0%）、睿智医药（0.0%）、太龙药业（-0.18%）、成都先导（-0.2%）、 义翘神州（-0.23%）、百花医药（-0.28%）、凯莱英（-0.33%） 本文源自：金融界 序代码股票名称现价涨跌幅主力资金净额主力资金净占比1300630普利退0.82-8.89-415.18 万-16.232301520万邦医药38.8-2.56-119.21万-1.503300759康龙化成22.41-2.52-2033.75万-4.674603739蔚 蓝生物13.6-1.73-655.01万-4.535603229奥翔药业8.13-1.69-488.23万-7.946000739普洛药业13.81- 1.642593.46万12.907688238和元生物5.71-1. ...